AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01263236
Drug: LY2940094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01263236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02910206
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil is given intravenously
Trial: NCT02425878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00619892
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
Trial: NCT00593567
Drug: gentamicin-collagen sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inserted daily into open ulcer
Trial: NCT02901067
Drug: Aspirin and Rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
Trial: NCT01289639
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1 capsule po qd
Trial: NCT00081224
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00081224
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02780713
Drug: AZD9496 (Reference)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9496 (Reference)
Trial: NCT02780713
Drug: AZD9496 Variant A
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9496 Variant A.
Trial: NCT02114229
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be given at a dose of 5 g/m\^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m\^2/dose.
Trial: NCT00844857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, once daily in the evening for 8 weeks.
Trial: NCT02114229
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given 1.5 g/m\^2 IV infusion during induction and consolidation.
Trial: NCT01910480
Drug: NBI-98854 50 mg capsule once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02436694
Drug: Local Anesthetic ropivacaíne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral and sciatic nerve block with ropivacaíne
Trial: NCT00842920
Drug: Simvastatin 60 mg
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg once daily
Trial: NCT00842920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet once daily
Trial: NCT00842920
Drug: Simvastatin 20 mg
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg once daily
Trial: NCT01875757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02285166
Drug: Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01661101
Drug: Placebo (for Dabigatran)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran placebo taken twice daily
Trial: NCT01661101
Drug: Placebo (for Omeprazole)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole placebo taken once daily
Trial: NCT02571101
Drug: CDFR0812-15/50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
Trial: NCT01615874
Drug: BDP hydrofluoroalkane (HFA) 80 mcg
RxNorm normalized name: HYDROFLUOROALKANE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP HFA 80 mcg, 2 inhalations BID
Trial: NCT01615874
Drug: Rescue medication: short-acting beta-2 agonist (SABA) MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Trial: NCT03519750
Drug: Melatonin 25 mg
RxNorm normalized name: melatonin 0.25 MG/ML
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24-48 hour monitoring of plasma melatonin as well as adverse events.
Trial: NCT01089608
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.
Trial: NCT01553318
Drug: Placebo (Sugar Pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
Trial: NCT01492374
Drug: Placebo matching BMS-241027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
Trial: NCT03496545
Drug: Acetaminophen 650 MG
RxNorm normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours
Trial: NCT00832572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ranolazine administered twice a day for 6 weeks
Trial: NCT00445172
Drug: E0302 (mecobalamin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection, mecobalamin twice a week.
Trial: NCT04219124
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT02919319
Drug: Placebo (Formulation B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft capsules matching ACT-541468 Formulation B
Trial: NCT02919319
Drug: Placebo tracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
Trial: NCT01746043
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by mouth 2 times a day for 6 weeks.
Trial: NCT00379522
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for arginine vasopressin
Trial: NCT02037191
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day
Trial: NCT02037191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day
Trial: NCT02420730
Drug: AGN-232411
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-232411 topical ophthalmic solution
Trial: NCT01014364
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
Trial: NCT01014364
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
Trial: NCT00184548
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04644705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to the interventional drug
Trial: NCT02502812
Drug: Clop F1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Trial: NCT02502812
Drug: Clop F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Trial: NCT02502812
Drug: Innovator
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Trial: NCT02171234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02171234
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01809301
Drug: TRIA-662
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00464646
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
Trial: NCT02953210
Drug: Fentanyl Hydrochloride
RxNorm normalized name: fentanyl hydrochloride
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous
Trial: NCT01261702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV
Trial: NCT01090570
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral capsules
Trial: NCT01346319
Drug: ABT-SLV361
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
Trial: NCT01346319
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
Trial: NCT02953210
Drug: Ketorolac Injectable Solution
RxNorm normalized name: ketorolac Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at the of the procedure
Trial: NCT03121001
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
Trial: NCT01624948
Drug: Mycophenolic acid dose reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
Trial: NCT04195243
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will take one pill, every 24 hr, during 7 days
Trial: NCT01293058
Drug: Intravenous
RxNorm normalized name: INTRAVENOUS SETS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
Trial: NCT03889626
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 bid po, d1-14, q3w
Trial: NCT02283996
Drug: Depot Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
Trial: NCT00835224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pill with an inactive substance that looks like the study drug.
Trial: NCT00945035
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
Trial: NCT00945035
Drug: Comparator: etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
Trial: NCT00319748
Drug: 852A
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
Trial: NCT02274389
Drug: No Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
Trial: NCT01604824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection in the abdomen
Trial: NCT01316913
Drug: GSK573719/GW642444 125/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125/25 mcg once-daily
Trial: NCT01316913
Drug: GSK573719/GW642444 62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5/25 mcg once-daily
Trial: NCT01316913
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mcg once-daily
Trial: NCT03564106
Drug: intraarticular radiofrequency + intraarticular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)
Trial: NCT03564106
Drug: intraarticular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraarticular methylprednisolone (30 mg)
Trial: NCT01972529
Drug: placebo (lower baseline platelet count)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg placebo (3 x 20 mg matching placebo tablets)
Trial: NCT01972529
Drug: placebo (higher baseline platelet count)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg placebo (2 x 20 mg matching placebo tablets)
Trial: NCT00617981
Drug: ThermoDox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
Trial: NCT00948298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
Trial: NCT00716092
Drug: Placebo (linagliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 28 days
Trial: NCT00716092
Drug: Placebo (sitagliptin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 28 days
Trial: NCT01208948
Drug: 1,2 dithiolane 3 valeric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg alpha lipoic acid per day
Trial: NCT00087958
Drug: XRP9881
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02571842
Drug: ACEI/ARB and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * ACEI or ARB will be prescribed as high as tolerable dose.~* Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks
Trial: NCT02714595
Drug: Best Available Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
Trial: NCT00578955
Drug: 1% Azithromycin and 0.1% Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Trial: NCT00578955
Drug: 1% Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Trial: NCT02587390
Drug: Simvastatin 80 mg
RxNorm normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Trial: NCT01896869
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
Trial: NCT00441701
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
Trial: NCT04786275
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard dose of 2 ug/kg after tetanic stimulation.
Trial: NCT04067726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
Trial: NCT04067726
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Trial: NCT03841058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pen to deliver a SC dose of placebo
Trial: NCT00542399
Drug: Levemir twice a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levemir twice a day
Trial: NCT00568061
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide for inhalation
Trial: NCT00568061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen gas (placebo) for inhalation
Trial: NCT03315338
Drug: Placebo oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.
Trial: NCT03533114
Drug: Placebo Oral Solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
Trial: NCT03475862
Drug: PTI-821 Non-manipulated
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTI-821 (oxycodone) 40 mg capsule extended release capsule
Trial: NCT03315338
Drug: CORT118335, 225mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as capsules for oral dosing
Trial: NCT03315338
Drug: CORT118335, 675mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as capsules for oral dosing
Trial: NCT00557544
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo per os
Trial: NCT03315338
Drug: CORT118335, 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as capsules for oral dosing
Trial: NCT03315338
Drug: CORT118335, 630mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as capsules for oral dosing
Trial: NCT00557544
Drug: ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketoprofen 1 mg/Kg
Trial: NCT03315338
Drug: CORT118335, 375mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as capsules for oral dosing
Trial: NCT03315338
Drug: CORT118335, 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as a suspension for oral dosing
Trial: NCT03315338
Drug: CORT118335, 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as a suspension for oral dosing
Trial: NCT03315338
Drug: CORT118335, 900mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as a suspension for oral dosing
Trial: NCT03315338
Drug: CORT118335, 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as a suspension for oral dosing
Trial: NCT01028014
Drug: Lactose capsule
RxNorm normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose capsule 1 by mouth daily for 2 weeks
Trial: NCT00244114
Drug: blood draw
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single blood sample collected to perform histamine release assay.
Trial: NCT00182455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 - 400 mg/day x 12 weeks
Trial: NCT03315338
Drug: CORT118335, 1500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 is supplied as a suspension for oral dosing